Кыргызстандын Саламаттык Сактоо
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Кирүү

Гастроинтестиналдык стромалдык шишиктердин молекулярдык профили жана клиникалык жыйынтыктары: 75 бейтаптын тажрыйбасы жана дуйнолук жыйынтыктар менен салыштыруу

https://dx.doi.org/10.51350/zdravkg2025.3.9.1.18.24
Гастроинтестиналдык стромалдык шишиктердин молекулярдык профили жана клиникалык жыйынтыктары: 75 бейтаптын тажрыйбасы жана дуйнолук жыйынтыктар менен салыштыруу
Полный текст Full text  

PDF (RUS)

PDF (RUS)
Корутунду Авторлор жөнүндө Шилтемелер

Корутунду

Киришүү. Гастроинтестиналдык стромалдык шишиктер (GIST) гетерогендүү неоплазмалар болуп эсептелет жана так диагноз коюу үчүн иммуногистохимиялык ырастоону талап кылат. Негизги маркерлерге CD117, DOG1, CD34, SMA, S-100 жана Ki-67 кирет. Изилдөөнүн максаты. Улуттук онкология жана гематология борборунун бейтаптарында GISTтин иммуногистохимиялык профилин баалоо жана алынган жыйынтыктарды эл аралык маалыматтар менен салыштыруу. Материалдар жана ыкмалар. 2019–2024-жылдар аралыгында морфологиялык жактан ырасталган GIST диагнозу коюлган 75 бейтапка ретроспективдүү анализ жүргүзүлдү. CD117, DOG1, CD34, SMA, S-100 жана Ki-67 экспрессиясы изилденди. Жыйынтыктар жана талкуу. CD117 94,7% бейтаптарда, DOG1 — 90,7%, CD34 — 69,3% учурларда оң болду. SMA жана S-100 экспрессиясы тиешелүүлүгүнө жараша 35,0% жана 8,0% бейтаптарда аныкталды. Ki-67 көрсөткүчү 1%дан 30%га чейин өзгөрүп, шишиктин агрессивдүүлүгүнүн деңгээлин көрсөткөн. Алынган маалыматтар эл аралык изилдөөлөр менен дал келип, Кыргызстанда молекулярдык ыкмаларга чектелген жеткиликтүүлүк шартында иммуногистохимиянын ишенимдүүлүгүн тастыктады. Жыйынтык. Иммуногистохимиялык изилдөө GISTтин диагностикасында жана прогнозунда негизги роль ойнойт. Стандарттык маркерлерди жана Ki-67 индекси баалоону колдонуу шишиктин биологиялык өзгөчөлүктөрүн аныктоого жана бейтаптарды башкаруунун тактикасын оптималдаштырууга мүмкүндүк берет.

Авторлор жөнүндө

Найзабекова Светлана Шамшикеевна, кандидат медицинских наук, врач химиотерапевт, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Исаева Назгул Казыбаевна, кандидат медицинских наук, заведующий отделением, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Толкунбекова Айжан Толкунбековна, врач химиотерапевт, младший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Кошалиева Айдана Нурлановна, врач химиотерапевт, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Naizabekova Svetlana Shamshikeevna, Candidate of Medical Sciences Chemotherapy physician, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Isaeva Nazgul Kazybaevna, Candidate of Medical Sciences, Head of Department, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Tolkunkbekova Aizhan Tolkunkbekovna, Chemotherapy physician, Junior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Koshalieva Aidana Nurlanovna, Chemotherapy physician, National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Найзабекова Светлана Шамшыкеевна, медицина илимдеринин кандидаты, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Исаева Назгүл Казыбаевна, медицина илимдеринин кандидаты, бөлүм башчы, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Толкункбекова Айжан Толкункбековна, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун кенже илимий кызматкери, Бишкек, Кыргыз Республикасы

Кошалиева Айдана Нурлановна, Улуттук онкология жана гематология борборунун химиотерапия боюнча дарыгери, Бишкек, Кыргыз Республикасы

Шилтемелер

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.

Негизги сөздөр
Гастроинтестиналдык стромалдык шишик (ГИСШ) , Иммуногистохимия , CD117 , DOG1 , Молекулярдык профиль , Экспрессия , Иматиниб , Максаттуу терапия , Онкология
Для цитирования

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Молекулярный профиль и клинические исходы гастроинтестина- льных стромальных опухолей: опыт 75 пациентов и сравнение с меж дународными данными. Научно-практический журнал «Здравоохранение Кыргызстана» 2025, № 3, с. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
For citation

Naizabekova S.Sh., Isaeva N.K., Tolkunbekova A.T., Kos halieva A.N.Molecular Profile and Clinical Outcomes of Gas trointestinal Stromal Tumors: Experience of 75 Patients and Comparison with International Data. Scientific practical jour nal “Health care of Kyrzstan” 2025, No.3, p. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Цитата үчүн

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Гастроинтестиналдык стромалдык шишиктердин молекулярдык профили жана клиникалык жыйынтыктары: 75 бейтаптын тажрыйбасы жана дуйнолук жыйынтыктар менен салыштыруу. Кыргызстандын саламаттык сактоо илимий-практикалык журналы
2025, № 3, б.18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Авторлор Найзабекова С.Ш., Исаева Н.К., Толкунбекова А.Т., Кошалиева А.Н.
Ссылка doi.org https://dx.doi.org/10.51350/zdravkg2025.3.9.1.18.24
Беттер 18-24
Негизги сөздөр Гастроинтестиналдык стромалдык шишик (ГИСШ), Иммуногистохимия, CD117, DOG1, Молекулярдык профиль, Экспрессия, Иматиниб, Максаттуу терапия, Онкология
Орусча
Об авторах

Найзабекова Светлана Шамшикеевна, кандидат медицинских наук, врач химиотерапевт, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Исаева Назгул Казыбаевна, кандидат медицинских наук, заведующий отделением, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Толкунбекова Айжан Толкунбековна, врач химиотерапевт, младший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Кошалиева Айдана Нурлановна, врач химиотерапевт, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика
Полный текст

PDF (RUS)
Список литературы

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.
Для цитирования

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Молекулярный профиль и клинические исходы гастроинтестина- льных стромальных опухолей: опыт 75 пациентов и сравнение с меж дународными данными. Научно-практический журнал «Здравоохранение Кыргызстана» 2025, № 3, с. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Англисче
About authors

Naizabekova Svetlana Shamshikeevna, Candidate of Medical Sciences Chemotherapy physician, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Isaeva Nazgul Kazybaevna, Candidate of Medical Sciences, Head of Department, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Tolkunkbekova Aizhan Tolkunkbekovna, Chemotherapy physician, Junior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Koshalieva Aidana Nurlanovna, Chemotherapy physician, National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic
Full text

PDF (RUS)
References

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.
For citation

Naizabekova S.Sh., Isaeva N.K., Tolkunbekova A.T., Kos halieva A.N.Molecular Profile and Clinical Outcomes of Gas trointestinal Stromal Tumors: Experience of 75 Patients and Comparison with International Data. Scientific practical jour nal “Health care of Kyrzstan” 2025, No.3, p. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Кыргызча
Авторлор жөнүндө

Найзабекова Светлана Шамшыкеевна, медицина илимдеринин кандидаты, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Исаева Назгүл Казыбаевна, медицина илимдеринин кандидаты, бөлүм башчы, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Толкункбекова Айжан Толкункбековна, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун кенже илимий кызматкери, Бишкек, Кыргыз Республикасы

Кошалиева Айдана Нурлановна, Улуттук онкология жана гематология борборунун химиотерапия боюнча дарыгери, Бишкек, Кыргыз Республикасы
Шилтемелер

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.
Цитата үчүн

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Гастроинтестиналдык стромалдык шишиктердин молекулярдык профили жана клиникалык жыйынтыктары: 75 бейтаптын тажрыйбасы жана дуйнолук жыйынтыктар менен салыштыруу. Кыргызстандын саламаттык сактоо илимий-практикалык журналы
2025, № 3, б.18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Көрүүлөр: 158
Copyright MAXXmarketing GmbH
JoomShopping Download & Support